Revisão Acesso aberto Revisado por pares

Cell Therapies

2013; Lippincott Williams & Wilkins; Volume: 44; Issue: 6_suppl_1 Linguagem: Inglês

10.1161/strokeaha.112.679605

ISSN

1524-4628

Autores

Sean I. Savitz,

Tópico(s)

Mesenchymal stem cell research

Resumo

HomeStrokeVol. 44, No. 6_suppl_1Cell Therapies Free AccessResearch ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessResearch ArticlePDF/EPUBCell TherapiesCareful Translation From Animals to Patients Sean I. Savitz, MD Sean I. SavitzSean I. Savitz From the Department of Neurology, University of Texas Health Science Center, Houston, TX. Originally published1 Jun 2013https://doi.org/10.1161/STROKEAHA.112.679605Stroke. 2013;44:S107–S109Therapeutic Phases of Stroke: Where do Cell Therapies Theoretically Fit?During the hyperacute stage of ischemic stroke, recanalization is the only approved therapeutic approach to improve outcome but is only applicable to the first few hours after symptom onset. There may, however, be other therapeutic windows to consider in the days to weeks after stroke. The inflammatory response after ischemic injury involves multiple interconnected processes both within the brain and in the periphery. During this same time period, there is a cascade of molecular signaling events leading to angiogenesis, neurogenesis, and axonal sprouting.1 Furthermore, neuroplasticity occurs not only at the molecular and cellular level within the peri-infarct zone, but also in areas remote from the infarct. Certain types of stem and progenitor cells represent a unique category of therapeutic opportunities because they may attenuate the postischemic proinflammatory response and may also engage, facilitate, and amplify many of the repair mechanisms operating during this acute to subacute stage of stroke (Figure). The temporal window for cell therapies during this time frame is not well-defined and likely depends on the intended targets, cell type, and delivery route.Download figureDownload PowerPointFigure. Various temporal windows can be envisioned that provide different mechanistic targets for cell therapies in stroke.In the chronic period of stroke, months after symptom onset, the potential therapeutic applications of cell therapies are also being studied in several different ways (Figure). The route of delivery has principally involved a stereotactic intracranial administration, with the intent of placing therapeutic cells in the infarct area. In fact, in the 1990s, there were preliminary clinical trials studying intracranial delivery of neural cells in patients with chronic stroke,2,3 studies that were designed in the wake of fetal transplantation approaches for patients with Parkinson disease. The goal of these pilot trials was to graft neural cells in the infarct cavity, but current intracranial clinical studies have been designed with a different intention to implant cells to stimulate local endogenous repair pathways. The concept of grafting cells to restore lost neural circuitry is still in an early stage of preclinical development.Various Cell Types Under Investigation for StrokeAlthough the mechanisms underlying how cell therapies enhance stroke recovery continue to be explored, the number and variety of cell types with therapeutic activity demonstrated in in vitro or in vivo studies has continued to expand in neurological disorders. These cell types can be categorized into embryonic, fetal, birth, and adult tissues. Among the most studied, the investigation of adult-derived cell therapies has surged during the past 10 years, when it was discovered that the bone marrow harbored mesenchymal stromal cells and hematopoietic stem cells that exert therapeutic effects in rodent stroke models, even when administered by intravenous delivery.4,5 Subsequently, a range of either purified cell types or mixed cell types from bone marrow, umbilical cord, adipose, and other tissues have been shown to improve neurological outcome in rodents with stroke. Our regenerative program has principally focused on bone marrow cells for autologous applications, where there are less ethical and practical concerns and less regulatory hurdles compared with embryonic and fetal tissues. However, advances in stem cell biology have recently made it possible to manufacture many purified cell types from different tissues, paving the way for the application of allogeneic off the shelf cell products that may not require concomitant immunosuppressive drugs.Bone Marrow and Stroke RepairThe bone marrow is an attractive source to derive or extract cells with therapeutic activity. Several studies have shown that the marrow contains several different stem cells involved in tissue homeostasis and repair.6 After stroke, the bone marrow releases different types of stem cells, including hematopoietic stem cells, as well as mesenchymal and endothelial progenitor cells, into the circulation. Once released into the bloodstream, some of these progenitor cells may even home to sites of ischemic injury in the brain.6 Thus, it is hypothesized that the bone marrow may participate in brain repair by mobilizing and releasing stem cells, but this concept still requires much further study. It is unclear how exactly stem cells (and in what proportion are they released) enter the brain after injury and stimulate recovery processes.Bone Marrow Mononuclear Cells for StrokeOur group became interested in the mononuclear fraction of bone marrow because this component of the marrow is enriched with different stem cell populations, and by the time we began exploring their therapeutic potential for stroke, several trials involving patients with acute myocardial infarction were suggesting that mononuclear cells (MNCs) improve left ventricular function.7 MNCs can be harvested from the marrow within hours, do not require culture, and can be immediately reinfused by systemic administration. MNCs are therefore suited for autologous applications in the acute setting. In contrast, the manufacture of a more purified progenitor population within the MNCs, for example, mesenchymal stromal cells, requires several passages in cell culture and cannot be applied in an autologous manner for acute injuries. However, it is important to point out that MNCs are a mixture of different cell types and principally contain immature and mature cells in the myeloid and lymphoid lineages; it is unclear which subpopulations within MNCs contribute to their potential benefits.Among the various preclinical studies on MNCs, investigators from different independent laboratories around the world have tested donor-derived syngeneic or autologous MNCs in a range of stroke models of mice, rats, and sheep8–12 (Table 1). In rodent models, MNCs, when administered by intravenous or intra-arterial delivery, lead to sustained long-term reductions in neurological deficits after stroke.8–10,13 We developed a clinically relevant model to simulate a clinical trial, in which MNCs are safely extracted from the bone marrow after stroke without causing limb impairment.11,13 Our studies have shown that intravenous autologous MNC infusion enhances recovery when administered within 3 days after stroke and that MNC-treated animals show a reduction in infarct maturation.11 Other laboratories have found that MNCs may reduce neurological deficits in a different model when administered up to 7 days after stroke.14 A similar therapeutic window within 3 days after stroke has been found testing the mononuclear fraction of umbilical cord cells in rodent stroke.15,16The mechanisms how any cell therapy exerts therapeutic effects in stroke models still remain poorly understood. After IV administration, MNCs do enter the brain but to a far less extent compared with their presence in the spleen, lungs, and liver.11 To assist their entry into the brain, MNCs may release NO to dilate vessels and facilitate their passage through the circulation.17 Once in the brain and other organs, MNCs exponentially decrease during the ensuing week because the cells are dying by apoptosis.11 These observations suggest that MNCs exert paracrine effects within target organs and then rapidly die off. In support of this hypothesis, we have identified that media derived from cultured MNCs contain many bioactive factors and can protect neurons exposed to hypoxia or when placed in contact with activated proinflammatory microglia.18 Microglia after ischemic stroke exert both pro- and anti-inflammatory effects within the peri-infarct. We have begun to identify that MNCs reduce proinflammatory microglia and upregulate anti-inflammatory/neurotrophic microglia (data not shown). Other laboratories have found that MNCs can increase vessel density and neurogenesis19 and protect neurons in the peri-infarct region.8 Overall, the data from multiple laboratories indicate that MNCs, like many other cell therapies such as umbilical cord–derived cells, target inflammatory and brain repair mechanisms in the acute to subacute stages of stroke.Clinical TrialsBecause MNCs have been found to exert therapeutic effects in animal stroke models from at least a half dozen independent laboratories, involving 3 different species (Table), my group has taken forward this particular cell therapy to patients with acute ischemic stroke. Our approach has been to design a trial that closely follows the published animal data, including time window, dose response, and delivery route. In our initial pilot study of 10 patients, a limited bone marrow harvest followed by intravenous reinfusion of autologous MNCs within 24 to 72 hours after stroke onset was feasible and safe.20 In comparing the 90-day functional outcome of the study patients against historical controls, nearly all the patients fell within or below the range of natural recovery of the historical cohort. We then completed enrollment on a total of 25 patients and have thus far not encountered any definite study related severe adverse events (data not published). Other centers have subsequently reported similar, small studies on the safety of autologous MNCs, when administered by intra-arterial injection at later time points after stroke.21FutureMuch remains to be studied with respect to elucidating the key mechanisms underlying how MNCs and other cell therapies enhance stroke recovery. Because further safety data are accumulating, more advanced clinical stage trials will be needed to begin testing their potential efficacy for stroke. Although MNCs are suited for autologous applications, studies attesting to the safety of manufactured allogeneic cells are escalating and carry the unique advantages of being far more homogenous and immediately available from storage (off the shelf product). The field of cell therapy for stroke is slowly advancing from the bench to the bedside, and it is hoped that as more clinical trials are launched, they will be guided by preclinical studies.22Table. Summary of Preclinical Data on Bone Marrow Mononuclear CellsCellsAutologous or donor-derived (syngeneic), not allogeneicSpeciesMice, rat, sheepTime window3–7 days, depending on stroke modelTypes of modelsSuture MCAO; photothrombosis; tandem CCAO/MCAO; endothelin-1; embolic modelRoutes of deliveryIV and IADose response10 million cells/kg optimal in the CCAO/MCAO modelLong-term behavioral data30–60 days after stroke in different modelsLesion sizeReduction in infarct cavity observed in different studiesCytokines/growth factorsIGF-1, IL-10, VEGF, bFGF, angiopoietin, PDGF, SDF-1These studies represent a summary from 7 different independent laboratories that are investigator initiated and not industry sponsored.bFGF indicates basic-fibroblast growth factor; CCAO, common carotid artery occlusion; IGF, insulin-like growth factor; IL, interleukin; MCAO, middle cerebral artery occlusion; PDGF, platelet-derived growth factor; SDF, stromal cell-derived factor; and VEGF, vascular endothelial growth factor.Sources of FundingThis work was supported from the following grants. National Institutes of Health R-01 NS071127 (Dr Savitz), R21 HD060978 (Dr Savitz), R21 NS064316 (Dr Savitz), T32NS007412, and Howard Hughes Medical Institute.DisclosuresDr Savitz received honoraria from Kyorin Pharmaceutical; is a consultant to KM Pharmaceutical, Celgene, Mesoblast, and Neuralstem; and has conducted sponsored research with Aldagen, Athersys, Celgene, and J&J.FootnotesCorrespondence to Sean I. Savitz, MD, Department of Neurology, University of Texas Health Science Center, Houston, TX 77030. E-mail [email protected]References1. Carmichael ST. Themes and strategies for studying the biology of stroke recovery in the poststroke epoch.Stroke. 2008; 39:1380–1388.LinkGoogle Scholar2. Savitz SI, Dinsmore J, Wu J, Henderson GV, Stieg P, Caplan LR. Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study.Cerebrovasc Dis. 2005; 20:101–107.CrossrefMedlineGoogle Scholar3. Kondziolka D, Steinberg GK, Wechsler L, Meltzer CC, Elder E, Gebel J, et al. Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial.J Neurosurg. 2005; 103:38–45.CrossrefMedlineGoogle Scholar4. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic.Lancet Neurol. 2009; 8:491–500.CrossrefMedlineGoogle Scholar5. Komatsu K, Honmou O, Suzuki J, Houkin K, Hamada H, Kocsis JD. Therapeutic time window of mesenchymal stem cells derived from bone marrow after cerebral ischemia.Brain Res. 2010; 1334:84–92.CrossrefMedlineGoogle Scholar6. Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB. The great migration of bone marrow-derived stem cells toward the ischemic brain: therapeutic implications for stroke and other neurological disorders.Prog Neurobiol. 2011; 95:213–228.CrossrefMedlineGoogle Scholar7. Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J, et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials.J Am Coll Cardiol. 2007; 50:1761–1767.CrossrefMedlineGoogle Scholar8. Giraldi-Guimaraes A, Rezende-Lima M, Bruno FP, Mendez-Otero R. Treatment with bone marrow mononuclear cells induces functional recovery and decreases neurodegeneration after sensorimotor cortical ischemia in rats.Brain Res. 2009(epub).CrossrefMedlineGoogle Scholar9. Iihoshi S, Honmou O, Houkin K, Hashi K, Kocsis JD. A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats.Brain Res. 2004; 1007:1–9.CrossrefMedlineGoogle Scholar10. Baker AH, Sica V, Work LM, Williams-Ignarro S, de Nigris F, Lerman LO, et al. Brain protection using autologous bone marrow cell, metalloproteinase inhibitors, and metabolic treatment in cerebral ischemia.Proc Natl Acad Sci USA. 2007; 104:3597–3602.CrossrefMedlineGoogle Scholar11. Yang B, Strong R, Sharma S, Brenneman M, Mallikarjunarao K, Xi X, et al. Therapeutic time window and dose response of autologous bone marrow mononuclear cells for ischemic stroke.J Neurosci Res. 2011; 89:833–839.CrossrefMedlineGoogle Scholar12. Boltze J, Nitzsche B, Geiger KD, Schoon HA. Histopathological investigation of different MCAO modalities and impact of autologous bone marrow mononuclear cell administration in an ovine stroke model.Transl Stroke.Res. 2011; 2:279–293.CrossrefMedlineGoogle Scholar13. Brenneman M, Sharma S, Harting M, Strong R, Cox CS, Aronowski J, et al. Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats.J Cereb Blood Flow Metab. 2010; 30:140–149.CrossrefMedlineGoogle Scholar14. de Vasconcelos Dos Santos A, da Costa Reis J, Diaz Paredes B, Moraes L, Jasmin , Giraldi-Guimarães A, et al. Therapeutic window for treatment of cortical ischemia with bone marrow-derived cells in rats.Brain Res. 2010; 1306:149–158.CrossrefMedlineGoogle Scholar15. Boltze J, Schmidt UR, Reich DM, Kranz A, Reymann KG, Strassburger M, et al. Determination of the therapeutic time window for human umbilical cord blood mononuclear cell transplantation following experimental stroke in rats.Cell Transplant. 2012; 21:1199–1211.CrossrefMedlineGoogle Scholar16. Newcomb JD, Brown WD, Rodriguez AI, Garbuzova-Davis S, Saporta S, Sanberg PR, et al. Behavioral alterations in Lewis rats following two-day continuous 3-nitropropionic acid administration.Neurotox Res. 2005; 8:259–266.CrossrefMedlineGoogle Scholar17. Kasam M, Yang B, Strong R, Schaar K, Misra V, Xi X, et al. Nitric oxide facilitates delivery and mediates improved outcome of autologous bone marrow mononuclear cells in a rodent stroke model.PLoS ONE. 2012; 7:e32793.CrossrefMedlineGoogle Scholar18. Sharma S, Yang B, Strong R, Xi X, Brenneman M, Grotta JC, et al. Bone marrow mononuclear cells protect neurons and modulate microglia in cell culture models of ischemic stroke.J Neurosci Res. 2010; 88:2869–2876.MedlineGoogle Scholar19. Nakano-Doi A, Nakagomi T, Fujikawa M, Nakagomi N, Kubo S, Lu S, et al. Bone marrow mononuclear cells promote proliferation of endogenous neural stem cells through vascular niches after cerebral infarction.Stem Cells. 2010; 28:1292–1302.MedlineGoogle Scholar20. Savitz SI, Misra V, Kasam M, Juneja H, Cox CS, Alderman S, et al. Intravenous autologous bone marrow mononuclear cells for ischemic stroke.Ann Neurol. 2011; 70:59–69.CrossrefMedlineGoogle Scholar21. Friedrich MA, Martins MP, Araújo MD, Klamt C, Vedolin L, Garicochea B, et al. Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke.Cell Transplant. 2012; 21(suppl 1):S13–S21.CrossrefMedlineGoogle Scholar22. Savitz SI, Chopp M, Deans R, Carmichael ST, Phinney D, Wechsler L. Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II.Stroke. 2011; 42:825–829.LinkGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Satani N, Parsha K and Savitz S (2022) Enhancing Stroke Recovery With Cellular Therapies Stroke, 10.1016/B978-0-323-69424-7.00062-4, (900-911.e5), . de Fátima dos Santos Sampaio M, Santana Bastos Boechat M, Augusto Gusman Cunha I, Gonzaga Pereira M, Cysne Coimbra N and Giraldi-Guimarães A (2021) Neurotrophin-3 upregulation associated with intravenous transplantation of bone marrow mononuclear cells induces axonal sprouting and motor functional recovery in the long term after neocortical ischaemia, Brain Research, 10.1016/j.brainres.2021.147292, 1758, (147292), Online publication date: 1-May-2021. Chung J, Chang W, Bang O, Moon G, Kim S, Kim S, Lee J, Sohn S and Kim Y (2021) Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke, Neurology, 10.1212/WNL.0000000000011440, 96:7, (e1012-e1023), Online publication date: 16-Feb-2021. Alam J, Krakovsky M, Germann U, Levy A and Zille M (2020) Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level, PLOS ONE, 10.1371/journal.pone.0233073, 15:12, (e0233073) Androvic P, Kirdajova D, Tureckova J, Zucha D, Rohlova E, Abaffy P, Kriska J, Valny M, Anderova M, Kubista M and Valihrach L (2020) Decoding the Transcriptional Response to Ischemic Stroke in Young and Aged Mouse Brain, Cell Reports, 10.1016/j.celrep.2020.107777, 31:11, (107777), Online publication date: 1-Jun-2020. Bang O and Kim E (2019) Mesenchymal Stem Cell-Derived Extracellular Vesicle Therapy for Stroke: Challenges and Progress, Frontiers in Neurology, 10.3389/fneur.2019.00211, 10 Bang O (2018) Stem cell therapy for stroke: lessons learned from recent successful randomized trials of interventional therapy for stroke, Precision and Future Medicine, 10.23838/pfm.2018.00058, 2:3, (109-116), Online publication date: 30-Sep-2018. Griffin J, Zlokovic B and Mosnier L (2018) Activated protein C, protease activated receptor 1, and neuroprotection, Blood, 10.1182/blood-2018-02-769026, 132:2, (159-169), Online publication date: 12-Jul-2018. Sandvig I, Gadjanski I, Vlaski-Lafarge M, Buzanska L, Loncaric D, Sarnowska A, Rodriguez L, Sandvig A and Ivanovic Z (2017) Strategies to Enhance Implantation and Survival of Stem Cells After Their Injection in Ischemic Neural Tissue, Stem Cells and Development, 10.1089/scd.2016.0268, 26:8, (554-565), Online publication date: 15-Apr-2017. Wang Y, Zhao Z, Rege S, Wang M, Si G, Zhou Y, Wang S, Griffin J, Goldman S and Zlokovic B (2016) 3K3A–activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice, Nature Medicine, 10.1038/nm.4154, 22:9, (1050-1055), Online publication date: 1-Sep-2016. Schmidt A and Minnerup J (2016) Promoting recovery from ischemic stroke, Expert Review of Neurotherapeutics, 10.1586/14737175.2016.1134324, 16:2, (173-186), Online publication date: 1-Feb-2016. Moniche F, Rosado-de-Castro P, Escudero I, Zapata E, de la Torre Laviana F, Mendez-Otero R, Carmona M, Piñero P, Bustamante A, Lebrato L, Cabezas J, Gonzalez A, de Freitas G and Montaner J (2016) Increasing Dose of Autologous Bone Marrow Mononuclear Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of Two Clinical Trials, Stem Cells International, 10.1155/2016/8657173, 2016, (1-8), . Yang B, Parsha K, Schaar K, Satani N, Xi X, Aronowski J and Savitz S (2016) Cryopreservation of Bone Marrow Mononuclear Cells Alters Their Viability and Subpopulation Composition but Not Their Treatment Effects in a Rodent Stroke Model, Stem Cells International, 10.1155/2016/5876836, 2016, (1-7), . Savitz S and Parsha K (2016) Enhancing Stroke Recovery with Cellular Therapies Stroke, 10.1016/B978-0-323-29544-4.00060-8, (981-991), . Misra V and Savitz S (2016) Cell Therapy in Ischemic Stroke Stem Cell and Gene Therapy for Cardiovascular Disease, 10.1016/B978-0-12-801888-0.00039-4, (497-507), . Nguyen H and Cramer S (2016) Cell-Based Therapies for the Treatment of Aphasia Neurobiology of Language, 10.1016/B978-0-12-407794-2.00086-9, (1085-1091), . Savitz S (2015) Developing Cellular Therapies for Stroke, Stroke, 46:7, (2026-2031), Online publication date: 1-Jul-2015. Wang J, Liu X, Lu H, Jiang C, Cui X, Yu L, Fu X, Li Q and Wang J (2015) CXCR4+CD45− BMMNC subpopulation is superior to unfractionated BMMNCs for protection after ischemic stroke in mice, Brain, Behavior, and Immunity, 10.1016/j.bbi.2014.12.015, 45, (98-108), Online publication date: 1-Mar-2015. Corbett D, Jeffers M, Nguemeni C, Gomez-Smith M and Livingston-Thomas J (2015) Lost in translation Sensorimotor Rehabilitation - At the Crossroads of Basic and Clinical Sciences, 10.1016/bs.pbr.2014.12.002, (413-434), . Detante O, Jaillard A, Moisan A, Barbieux M, Favre I, Garambois K, Hommel M and Remy C (2014) Biotherapies in stroke, Revue Neurologique, 10.1016/j.neurol.2014.10.005, 170:12, (779-798), Online publication date: 1-Dec-2014. Tajiri N, Quach D, Kaneko Y, Wu S, Lee D, Lam T, Hayama K, Hazel T, Johe K, Wu M, Borlongan C and Mezey E (2014) Behavioral and Histopathological Assessment of Adult Ischemic Rat Brains after Intracerebral Transplantation of NSI-566RSC Cell Lines, PLoS ONE, 10.1371/journal.pone.0091408, 9:3, (e91408) Carmichael S and Krakauer J (2013) The Promise of Neuro-Recovery After Stroke: Introduction, Stroke, 44:6_suppl_1, (S103-S103), Online publication date: 1-Jun-2013. June 2013Vol 44, Issue 6_suppl_1 Advertisement Article InformationMetrics © 2013 American Heart Association, Inc.https://doi.org/10.1161/STROKEAHA.112.679605PMID: 23709699 Manuscript receivedOctober 6, 2012Manuscript acceptedMarch 6, 2013Originally publishedJune 1, 2013 Keywordsbone marrowcell therapyinflammationrepairPDF download Advertisement

Referência(s)